Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?

被引：0
|
作者：
Gomez Casares, Maria Teresa [1 ]
Leon, Leticia G. [1 ]
机构：
[1] Hosp Univ Dr Negrin, Serv Hematol, Mol Biol Lab, Las Palmas Gran Canaria, Spain
来源：
MEDICINA CLINICA | 2013年 / 141卷 / 03期
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; GIMEMA WORKING PARTY; CHROMOSOMAL-ABNORMALITIES; IMATINIB; INTOLERANT; FREQUENCY; THERAPY; BCR/ABL; CML;
D O I：
10.1016/j.medcli.2012.12.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：111 / 113
页数：3
相关论文
共 50 条
  • [11] BCR- ABL KINASE MUTATIONS TO IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA
    Thungappa, S. Chiradoni
    Singh, T.
    Rashmi, N. R.
    Lokanatha, D.
    Rajshekar, H.
    Lakshmaiah, K. C.
    Babu, K. G.
    Suresh, T. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 357 - 357
  • [12] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Lee, Hyewon
    Basso, Igor Novitzky
    Kim, Dennis Dong Hwan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 632 - 641
  • [13] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Hyewon Lee
    Igor Novitzky Basso
    Dennis Dong Hwan Kim
    International Journal of Hematology, 2021, 113 : 632 - 641
  • [14] Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Baccarani, Michele
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Palandri, Francesca
    Rosti, Gianantonio
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (03) : 397 - 406
  • [15] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [16] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [17] Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
    Patel, Ami B.
    O'Hare, Thomas
    Deininger, Michael W.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 589 - +
  • [18] Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
    Cortes, Jorge
    Jabbour, Elias
    Kantarjian, Hagop
    Yin, C. Cameron
    Shan, Jianqin
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Giles, Francis
    Breeden, Megan
    Reeves, Nubia
    Wierda, William G.
    Jones, Dan
    BLOOD, 2007, 110 (12) : 4005 - 4011
  • [19] GENETIC MUTATIONS OUTSIDE BCR-ABL1 DETERMINING TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA
    Aref, Salah
    Abdalla, Nada
    Muller, Martin
    El Sharaway, Solofa
    Aziz, Sherin Abdel
    Sauselle, Sussane
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 : 17 - 17
  • [20] Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia
    Gado, Sarah
    Hassan, Mohammed Al-Kassim
    Kisla, Mehmet Murat
    Ates-Alagoz, Zeynep
    MEDICINAL CHEMISTRY, 2024,
12345